Drug Type Small molecule drug |
Synonyms Rislenemdaz, MK-0657 |
Target |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H23FN4O2 |
InChIKeyRECBFDWSXWAXHY-IAGOWNOFSA-N |
CAS Registry808732-98-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Major depressive disorder, moderate (MDD) | Phase 2 | US | 01 Jun 2015 | |
Depression | Phase 2 | US | 01 Nov 2013 | |
Suicidal Ideation | Phase 2 | US | 01 Nov 2013 | |
Depressive Disorder, Major | Phase 2 | US | 01 Nov 2013 | |
Dyskinesias | Phase 1 | - | 01 May 2007 | |
Parkinson Disease | Phase 1 | - | 01 May 2007 | |
Hypotension, Orthostatic | Phase 1 | US | - |
Phase 1 | 22 | wbqvbeenjf(vpdzpdpqpe) = pzylowkjwa driwssreju (havnzrkzhn, -5.1 to 0.4) View more | Negative | 01 Jan 2017 |